P3 PROSTATE CANCER FORUM 2026
Perspectives, Possibilities, Progress
On-Demand Education
P3 PROSTATE CANCER FORUM 2026 brought together over 140 oncology healthcare professionals and a faculty of 24 healthcare professionals to discuss current approaches to prostate cancer management.
This on-demand hub gives you access to a selection of those sessions. The materials are intended to support day-to-day decision-making, encourage multidisciplinary discussion and sit alongside existing guidelines and local protocols.
The videos and PowerPoint presentations have been developed and funded by Bayer plc.
Watch P3 2026 Highlights:
Get a quick overview of the meeting before you dive into the full sessions. The highlights video includes:
- Faculty perspectives on the aims and structure of P3.
- Main themes and discussion points from across the agenda.
- HCP reflections on what they plan to consider or approach differently in practice.
Prof. Alison Birtle, Consultant Clinical Oncologist, Rosemere Cancer Centre, Lancashire Teaching Hospitals NHS Foundation Trust (Royal Preston Hospital)
Downloadable Slide Sets:
DOWNLOAD SLIDES →
Personalising Treatment in mHSPC - ARI Clinical Landscape
Presented by Prof. Vincent Khoo (Royal Marsden & St George's NHS Foundation Hospitals) - Summarising ARANOTE, ARASENS, and STOPCAP data as presented, with key points on treatment options, intensification strategies, and shared decision-making.
DOWNLOAD SLIDES →
Delivering Personalised Prostate Cancer Care via Shared Decision-Making - Practical Frameworks for mHSPC
Presented by Dr. Simon Hughes (Guy's & St. Thomas' NHS Foundation Trust) - Covering shared decision-making principles in mHSPC, with key points on treatment intensification, quality-of-life trade-offs, and aligning evidence with patient values.
Please refer to the NUBEQA summary of product characteristics before prescribing.
Abbreviations: ARI, androgen receptor inhibitor; mHSPC, metastatic hormone‑sensitive prostate cancer; MDT, multidisciplinary team.
PP-NUB-GB-3064 | June 2026